Needham downgraded Day One Biopharmaceuticals (DAWN) to Hold from Buy after Servier agreed to acquire Day One for $21.50 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals downgraded to Neutral from Outperform at Wedbush
- Day One Biopharmaceuticals downgraded to Hold from Buy at JonesResearch
- Servier to Acquire Day One Biopharmaceuticals in Merger
- Day One Biopharmaceuticals trading resumes
- Servier to acquire Day One for $21.50 per share in cash